Understanding the immune response to Leishmania infection and identifying biomarkers
that correlate with protection are crucial for developing effective vaccines. One intriguing …

Background Post-kala-azar dermal leishmaniasis (PKDL) is a dermatosis which can occur
after successful treatment of visceral leishmaniasis (VL) and is a public health problem in VL …

Infectious diseases like leishmaniasis, malaria, HIV, tuberculosis, leprosy and filariasis are
responsible for an immense burden on public health systems. Among these, leishmaniasis …

Adenoviruses typically cause mild illnesses, but severe diseases may occur primarily in
immunodeficient individuals, particularly children. Recently, adenoviruses have garnered …

The leishmaniases are globally important parasitic diseases for which no human vaccines
are currently available. To facilitate vaccine development, we conducted an open label …

Background. In a recent Phase IIa clinical trial, the candidate leishmaniasis vaccine ChAd63-
KH was shown to be safe and immunogenic in Sudanese patients with post kala-azar …

Leishmaniasis is an ongoing public health crisis and asks for unabated addressal by all
stakeholders. Efforts to eradicate the disease have been underway for over a decade. While …

The potentially fatal visceral leishmaniasis (VL) disease in human is endemic to tropical
world and caused by protozoan parasites Leishmania donovani (in the Indian subcontinent …

Post kala-azar dermal leishmaniasis (PKDL) cases play a vital role in maintaining the
parasite reservoir during interepidemic periods of visceral leishmaniasis. Timely diagnosis …

Visceral leishmaniasis (VL), a neglected tropical disease, is caused by the parasite
Leishmania donovani complex. Whereas the transmission of L. donovani infection is …